Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29782139 | 1.00 | HPGD (0.48) | HPGDTSHRNPC1RAB9AMAPT | |
| SCHEMBL14638925 | 0.86 | TAS1R3 (0.38) | HPGDNPC1RAB9AMAPTMEN1 | |
| SCHEMBL2653478 | 0.83 | VCAM1 (0.39) | HPGDTSHRMEN1KMT2AKDM4E | |
| SCHEMBL926435 | 0.81 | HPGD (0.44) | HPGDTSHRNPC1RAB9AMAPT | |
| SCHEMBL8017852 | 0.81 | TSHR (0.53) | HPGDTSHRNPC1RAB9AMAPT | |
| SCHEMBL21804733 | 0.79 | PARP1 (0.46) | HPGDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL30031180 | 0.79 | PARP1 (0.46) | HPGDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL5961929 | 0.79 | HPGD (0.43) | HPGDTSHRNPC1RAB9AMAPT | |
| SCHEMBL2647013 | 0.78 | HPGD (0.54) | HPGDTSHRNPC1RAB9AMAPT | |
| SCHEMBL13734747 | 0.77 | TSHR (0.56) | HPGDTSHRMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115417738-B | Photo-induced alpha-hydrofluorination method for diazoaryl ester compound | 哈尔滨工业大学（深圳） | 2023-10-03 | — | — | CN | claimed |
| CN-115417738-A | Photoinduced diazoaryl ester compound alpha-hydrofluorination method | 哈尔滨工业大学（深圳） | 2022-12-02 | — | — | CN | claimed |
| US-12582719-B2 | Chimeric compounds and methods of managing neurological disorders or conditions | EMORY UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| CN-115417738-B | Photo-induced alpha-hydrofluorination method for diazoaryl ester compound | 哈尔滨工业大学（深圳） | 2023-10-03 | — | — | CN | disclosed |
| CN-115417738-A | Photoinduced diazoaryl ester compound alpha-hydrofluorination method | 哈尔滨工业大学（深圳） | 2022-12-02 | — | — | CN | disclosed |
| CN-109988090-B | Tetrahydropyrrole derivative and synthetic method and application thereof | 华东师范大学 | 2022-07-22 | — | — | CN | disclosed |
| US-20220133892-A1 | Chimeric Compounds and Methods of Managing Neurological Disorders or Conditions | UNIV EMORY (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3930746-A1 | CHIMERIC COMPOUNDS AND METHODS OF MANAGING NEUROLOGICAL DISORDERS OR CONDITIONS | Emory University (US) | 2022-01-05 | — | — | EP | disclosed |
| CN-109988090-A | A kind of pyrrolidine derivative and its synthetic method and application | 华东师范大学 | 2019-07-09 | — | — | CN | disclosed |
| US-10207984-B2 | Cyclopropyl derivatives and methods of use | EMORY UNIVERSITY (US) | 2019-02-19 | — | — | US | disclosed |
| US-10093609-B2 | TAK1 kinase inhibitors, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2018-10-09 | — | — | US | disclosed |
| US-20090048329-A1 | Substituted Pyrrolidine Compounds With Central Nervous System Activity | NIH-DEITR | 2009-02-19 | — | — | US | disclosed |
| WO-2009002923-A1 | SUBSTITUTED PYRROLIDINE COMPOUNDS WITH CENTRAL NERVOUS SYSTEM ACTIVITY | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1305301-B1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-6608218-B2 | Such as 1-(cyclopentyloxy-(3,4-dichloro-phenyl)-acetyl)-3-methyl-urea for treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2003-08-19 | — | — | US | disclosed |
| EP-1305301-A1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-02 | — | — | EP | disclosed |
| US-20020198200-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | KESTER ROBERT F (US) | 2002-12-26 | — | — | US | disclosed |
| US-6486184-B2 | 1-(CYCLOPENTYLOXY-(3,4-DICHLORO- PHENYL)-ACETYL)-3-METHYL-UREA FOR EXAMPLE; USE IN TREATING HYPERGLYCEMIA CHARACTERISTIC OF ALL TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-11-26 | — | — | US | disclosed |
| US-20020042512-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | KESTER ROBERT F (US) | 2002-04-11 | — | — | US | disclosed |
| WO-2002008209-A1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048329-A1 | Substituted Pyrrolidine Compounds With Central Nervous System Activity | SLC6A3, SLC18A2, SLC6A2 | HPGD 2321/4885TSHR 1153/4885NPC1 276/4885 |
| US-20020042512-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | GCK, GCKR, ALDOA | HPGD 1396/4885TSHR 3506/4885NPC1 4358/4885 |
| US-10093609-B2 | TAK1 kinase inhibitors, compositions, and uses related thereto | TAB1, MAP3K1, MAP3K6 | HPGD 2646/4885TSHR 4115/4885NPC1 1648/4885 |
| US-10207984-B2 | Cyclopropyl derivatives and methods of use | CNR2, FKBP8, FKBP5 | HPGD 249/4885TSHR 3988/4885NPC1 2820/4885 |
| US-20220133892-A1 | Chimeric Compounds and Methods of Managing Neurological Disorders or Conditions | MAOA, HNMT, HDAC6 | HPGD 2129/4885TSHR 1974/4885NPC1 2010/4885 |
| US-12582719-B2 | Chimeric compounds and methods of managing neurological disorders or conditions | SLC6A4, HTR4, HTR1A | HPGD 3078/4885TSHR 206/4885NPC1 963/4885 |
| US-20020198200-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | GCK, GCKR, ALDOA | HPGD 1297/4885TSHR 3583/4885NPC1 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.